Treatment of Rabbit Bullous Keratopathy with Precursors Derived from Cultured Human Corneal Endothelium
Overview
Affiliations
Purpose: To establish a method for the mass production of human corneal endothelium (HCE) precursors and the therapeutic application of these cells in a rabbit CE-deficiency model.
Methods: A sphere-forming assay was performed to produce precursors from cultured HCE. Various marker expressions were examined in the sphere colonies, and their progenies by immunocytochemistry and reverse transcription-polymerase chain reaction (RT-PCR). The transport activity of the sphere-derived cell sheet was evaluated by the Ussing chamber system. DiI-labeled precursors obtained from cultured HCE were injected the anterior chamber of the eye in a rabbit CE-deficiency model, and the eye-down position was maintained for 24 hours for attachment to Descemet's membrane (sphere eye-down group). The sphere eye-down and control groups, observed for 28 days after surgery, underwent histologic and fluorescence microscopic examinations.
Results: Cultured HCE formed primary and secondary sphere colonies. The spheres expressed alpha-smooth muscle actin and nestin, and progeny expressed alpha-smooth muscle actin, confirmed by RT-PCR. The progeny showed an HCE-like hexagonal shape, were confluent, and had adequate transport activity. Mean corneal thickness in the sphere eye-down group was significantly less than in the other control groups 14, 21, and 28 days (P < 0.006) after surgery. The HCE-like hexagonal cells detected on the Descemet's membrane are DiI-positive in the sphere eye-down group.
Conclusions: The findings demonstrate that culture of HCE can promote mass production of HCE precursors, determined by sphere-forming assay. Injection of precursors derived from cultured HCE into the anterior chamber is an effective treatment strategy for CE deficiency in a rabbit model.
Biomaterials used for tissue engineering of barrier-forming cell monolayers in the eye.
Sasseville S, Karami S, Tchatchouang A, Charpentier P, Anney P, Gobert D Front Bioeng Biotechnol. 2023; 11:1269385.
PMID: 37840667 PMC: 10569698. DOI: 10.3389/fbioe.2023.1269385.
Corneal Endothelial-like Cells Derived from Induced Pluripotent Stem Cells for Cell Therapy.
Ng X, Peh G, Yam G, Tay H, Mehta J Int J Mol Sci. 2023; 24(15).
PMID: 37569804 PMC: 10418878. DOI: 10.3390/ijms241512433.
Shin H, Min J, Kim N, Seo K, Chin H, Lee S Korean J Ophthalmol. 2022; 37(1):31-41.
PMID: 36549303 PMC: 9935058. DOI: 10.3341/kjo.2022.0133.
Chew L, Jun A, Barnett B Exp Eye Res. 2022; 224:109241.
PMID: 36075460 PMC: 10782848. DOI: 10.1016/j.exer.2022.109241.
Evolution of therapies for the corneal endothelium: past, present and future approaches.
Ong H, Ang M, Mehta J Br J Ophthalmol. 2020; 105(4):454-467.
PMID: 32709756 PMC: 8005807. DOI: 10.1136/bjophthalmol-2020-316149.